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Open access under CC BModulation of DNA repair pathways in oncology has been an area of intense interest in the last decade,
not least as a consequence of the promising clinical activity of poly(ADP-ribose) polymerase (PARP) inhib-
itors. In this review article, we highlight inhibitors of the phosphatidylinositol 3-kinase related kinase
(PIKK) family as of potential interest in the treatment of cancer, both in combination with DNA-damaging
therapies and as stand-alone agents.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.13It is estimated that each of the approximately 10 cells com-
prising the human body suffers many thousands of DNA damaging
events every day, and, if unrepaired or aberrantly repaired, the
resulting DNA lesions may prove lethal to the cell or give rise to
dangerous mutations.1 Fortunately, cells have evolved efﬁcient
processes for the repair of DNA damage, collectively known as
the DNA-damage response (DDR). Although less prevalent than
other DNA lesions, the DNA double-strand break (DSB) is consid-
ered to be the most cytotoxic and difﬁcult to repair, and there is
evidence to suggest that a single DSB may prove lethal to a cell.2
Two principal mechanisms are responsible for the repair of DSBs,
namely the error-free homologous recombination (HR) process,
and non-homologous end joining (NHEJ), which is an error prone
ligation mechanism. Whereas HR repair is by necessity restricted
to S and G2, NHEJ may operate at any phase of the mitotic cell cy-
cle, although this repair process occurs predominantly in G1 and
G0.1,3 Importantly, initiation of the DDR as a consequence of DSB
detection has far-reaching implications within a cell, resulting in
the activation of a complex signalling network that modulates cell
cycle progression, gene expression and protein synthesis.1,4 Mem-
bers of an atypical class of protein kinases termed the phosphati-
dylinositol (PI) 3-kinase related kinase (PIKK) family are major
players in the detection, signalling and repair of DNA DSBs.
The PIKK family of serine/threonine kinases comprises six
established members that are structurally different from classicalY-NC-ND license.protein kinases, and whose kinase domains more closely resemble
those of the PI 3-kinase family of phospholipid kinases (Fig. 1).4–6
Thus, ataxia telangiectasia mutated (ATM), ataxia telangiectasia-
and RAD3-related (ATR), mammalian target of rapamycin (mTOR),
human suppressor of morphogenesis in genitalia-1(hSMG-1), and
the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs)
exhibit protein kinase activity. The sixth known member of the
PIKK family, transformation/transcription associated protein
(TRRAP) is devoid of kinase activity, and serves as an essential
component of the SAGA and PCAF histone acetyltransferase com-
plexes. The importance of mTOR as a cancer therapeutic target
has been extensively reviewed elsewhere,7,8 and as this kinase
does not play a signiﬁcant role in the DDR process, will not be dis-
cussed further. Three members of the PIKK family, DNA-PK, ATM
and ATR, play prominent roles in the cellular response to DNA
damage through the detection and repair of DSBs. DNA-PK, a het-
erotrimeric enzyme comprising a catalytic subunit (DNA-PKcs)
and two Ku subunits, is a key component of the NHEJ process of
DNA DSB repair,9,10 whereas ATM responds to DSBs induced, for
example by ionising radiation (IR), by signalling to downstream re-
sponse factors involved in cell cycle regulation and DNA repair.4,6
By contrast, ATR is activated by single strand breaks, and operates
in conjunction with the so called partner protein ATRIP to recog-
nise these single strands of DNA coated with replication protein
A (RPA). Subsequent phosphorylation of Chk1 by ATR then culmi-
nates in cell cycle arrest.11
Paradoxically, DNA-repair processes within cancer cells also
constitute a potential mechanism of resistance to DNA-damaging
Figure 1. The phosphatidylinositol 3-kinase-like kinase (PIKK) family of atypical protein kinases. (Reproduced from Ref. 6 with permission).
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of increasing therapeutic interest as chemo- and radio-sensitising
agents in the treatment of cancer.12–14 Perhaps more interestingly,
DDR defects are a common feature of cancer and the ‘mutator-phe-
notype’ associated with the resultant genomic instability may offer
a survival advantage over normal tissues, albeit that tumour
dependency (‘addiction’) to the remaining DNA-repair pathways
can result. This offers the exciting opportunity of achieving selec-
tive antitumour activity through pharmacological inhibition of an
essential DNA repair pathway, as has been elegantly demonstrated
by the synthetic lethality observed with poly(ADP-ribose) poly-
merase-1 (PARP-1) inhibitors in BRCA1 and BRCA2 deﬁcient tu-
mours.1,14 Indeed, the possibility of achieving synthetic lethality
has been a key factor in the recent renaissance of interest in the
DDR modulation ﬁeld. In this Digest, we review progress in the
development of pharmacological inhibitors of DNA-PK, ATM and
ATR, highlighting opportunities and challenges associated with
inhibition of these protein kinase targets.O
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Figure 2. Crystal structure of LY294002 (4) in complex with the ATP-binding
domain of PI 3-Kc.19Perhaps unsurprisingly, given the limited similarities within the
ATP-binding domains of the PIKK and PI 3-kinase families, the ear-
liest examples of PIKK inhibitors were identiﬁed largely through
counter-screening of PI 3-K inhibitors. Thus, the fungal metabolite
wortmannin (1), a potent, non-selective and irreversible inhibitor
of PI 3-kinases, is also active against PIKK family members includ-
ing mTOR and DNA-PK as well as polo-like kinase 1 (PLK1).15 Izzard
et al. have demonstrated that 1 binds covalently within the ATP-
binding domain of DNA-PKcs analogously to PI 3-kinase, and inhib-
its the kinase with a Ki of 120 nM.16 Sensitisation of cells to IR by
micromolar concentrations of 1 has been ascribed to prevention
of DNA DSB repair, as a consequence of DNA-PK inhibition.17
Although extensive structure–activity studies (SARs) have been
conducted with 1,15 the lack of selectivity, poor stability and toxic-
ity associated with this agent have largely mitigated against fur-
ther clinical development.Identiﬁcation of the chromone derivative LY294002 (4; X = O)
stemmed from studieswith the promiscuous natural product kinase
inhibitor quercetin (2). SAR studies with 2 revealed that the 2-mor-
pholinochromenone (3) exhibited some selectivity for PI 3-K over
other kinases compared with 2, which was improved by the intro-
duction of an 8-phenyl group (4).18 The importance of the oxygen
of the morpholine substituent of 4 was also reported, and while
replacement by thiomorpholine (5) dramatically reduced potency,
the piperidine derivative (6) proved essentially devoid of activity,
indicative of a crucial hydrogen bond acceptor function for themor-
pholine oxygen. The key role of themorpholine substituent of 4was
subsequently conﬁrmedbyX-ray crystallography;19 the structure of
4 in complexwith human PI 3-Kc revealed that themorpholine oxy-
gen makes a hydrogen bond interaction with the backbone amide
group of Val-882 within the ATP-binding domain of the kinase
(Fig. 2). Notably, quercetin (2) binds in a very different orientation
from 4, with the carbonyl group making the corresponding interac-
tion with Val-882, while the ketone oxygen of the D-ring of 1 fulﬁls
this interaction in the wortmannin-PI 3-Kc complex.
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LY294002 (4) continues to be described as a selective PI 3-K
inhibitor, but comparable low micromolar potency has been ob-
served against a number of other kinases including mTOR and
DNA-PK.16,20 In an early attempt to confer kinase selectivity, a ser-
ies of derivatives of 4 was synthesised where a 2-morpholino-
chromenone derivative was coupled to the hsp90 modulator
geldanamycin through a spacer group.21 Binding to hsp90 via the
geldanamycin moiety was expected to present the kinase inhibitor
to a target ATP-binding domain only when a favourable association
occurred between hsp90 and the appropriate kinase to form a ter-
nary complex. A correlation between the nature and position of the
linker and potency of inhibition of PI 3-K and DNA-PK was ad-
duced, with the dimeric compound 7 combining good selectivity
for DNA-PK (IC50 = 6.1 lM) over PI 3-K (IC50 > 500 lM) with rea-
sonable afﬁnity for hsp90 (EC50 = 4 lM). However, no data were
presented to demonstrate kinase selectivity in the cellular setting.
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Although wortmannin (1) served as a valuable tool compound
in pioneering investigations to elucidate the role of DNA-PK in
DNA repair, the poor selectivity of this agent has generally limited
its use to in vitro studies. Early efforts to develop small-molecule
inhibitors with an improved selectivity proﬁle resulted in the iden-N
N
N
R
N
O
13
N
14
N
N
R
R
RO
R
N
15
N
N
ON
Me
Me
Ntiﬁcation of the pyridone derivative OK-1035 (8), selected follow-
ing a high-throughput screen of some 10,000 microbial extracts
and synthetic compounds.22 Kinetic analysis of 8 demonstrated
ATP-competitive inhibition of DNA-PK (IC50 = 8 lM) and limited
structure–activity studies established the importance of the 6-
hydrazonomethyl substituent. Thus, whereas the correspondingoxime (9) exhibited potency comparable with 8, the 6-methylpyri-
done milrinone (10) was inactive as a DNA-PK-inhibitor. However,
only very limited kinase counter-screening of 8 was reported, with
no data being presented regarding inhibition of other PIKK or PI 3-
K family members. In subsequent studies, 8 was shown to potenti-
ate DNA damage in DSB repair-proﬁcient, but not DSB repair-deﬁ-
cient, L5178 murine lymphoma cells following exposure to IR,
implying that the DSB repair defect was a consequence of impaired
DNA-PK activity.23 The reported activity of 8 as a DNA-PK inhibitor
prompted the Newcastle research group to develop a synthetic
route to this heterocycle, and the structure was unambiguously
conﬁrmed by X-ray crystallography. Surprisingly, 8 proved some
12-fold less potent as a DNA-PK inhibitor (IC50 = 100 lM) in this
group’s assay.24
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DNA-PK inhibitory activity has also been reported for a number
of other chemotypes. The neuroleptic drug triﬂuoperazine (11) was
identiﬁed as a modest inhibitor (IC50 100–200 lM) following
evaluation of a panel of phenothiazines, although cellular studies
were reportedly complicated by the direct pro-apoptotic activity
of 11. Thus, the phenothiazine appears to elicit direct apoptotic
cleavage of DNA-PKcs in addition to inhibiting kinase activity.25
Screening of a library of 3-substituted indolin-2-ones resulted in
the identiﬁcation of SU11752 (12) as an ATP-competitive DNA-PK
inhibitor (IC50 = 0.13 lM), and 12 was shown to impede DNA DSB
repair in a human glioma cell line following exposure to ionising
radiation or the DNA DSB eliciting agent calicheamicin.26 Although
selectivity over PI 3-Kc and ATM was demonstrated, the activity of
12 against other kinases was not described. Two recently published
Merck patents disclose morpholinylquinazolines (13) and pyrazol-
oquinolines (14), respectively, as cell-potent DNA-PK inhibitors.27
Interestingly, NVP-BEZ-235 (15), a dual mTOR-PI 3-kinase inhibitor
currently in clinical trials, is also reportedly a potent DNA-PK and
ATM inhibitor in both enzyme and cellular assays,28,29 despite re-
ports to the contrary by Novartis.30The observation that vanillin (16) sensitised cells to the lethal
effects of ionising radiation, prompted Durant and Karran to eval-
uate the mechanism of action of this natural product.31 Although
only a very weak DNA-PK inhibitor (IC50 = 1.5 mM), non-cytotoxic
concentrations of 16were found to inhibit NHEJ and potentiate the
cytotoxicity of cisplatin, but not IR or UV radiation, in several
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pounds identiﬁed 4,5-dimethoxy-2-nitrobenzaldehyde (17) and 2-
bromo-4,5-dimethoxybenzaldehyde (18) as more potent DNA-PK
inhibitors, with IC50 values of 15 and 30 lM, respectively. Deriva-
tives lacking an aldehyde function were inactive, and the authors
proposed that compounds 16–18 serve as irreversible DNA-PK
inhibitors through reaction of the aldehyde with a catalytic lysine
(Lys-3751) to generate a Schiff base, albeit that no kinetic data
were presented to support this.O
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RInterestingly, the benzaldehyde derivative 19 was indepen-
dently identiﬁed as a sub-micromolar DNA-PK inhibitor (IC50 =
400 nM) from a small-molecule library screen conducted by the
ICOS Corporation (now a subsidiary of Lilly Pharmaceuticals).32
Hit-to-lead optimisation studies were focussed on the arylmorpho-O N
O
X
22; X = O
27; X = CH2
N
N N
O
O
23
X
O
N
O
24; X = O
25; X = S
26; X = NH
MeOline motif, with the acetophenone derivative (20; DNA-PK,
IC50 = 120 nM) exhibiting good selectivity for DNA-PK over a range
of kinases including ATM, ATR andmTOR. In vitro and in vivo poten-
tiation of the activity of DNA DSB-inducing agents, in tandem with
low inherent cytotoxicity, was also observed for 20. Further elabo-
ration of this series afforded IC87361 (21; DNA-PK, IC50 = 34 nM),
a chromone differing from LY294002 (4) by virtue of a 5-hydroxy
group, and the fact that the morpholine substituent resides on the
phenyl rather than the pyranone ring. Comparative in vitro studies
utilising wild-type and DNA-PK defective severe combined immu-
nodeﬁcient (SCID) endothelial cell lines, demonstrated that radio-
sensitisation by 21 occurred exclusively in wild-type, but not in
SCID cells, consistent with the compound functioning via DNA-PK
inhibition.33 The activity of 21 as a radiation-sensitising agent was
conﬁrmed in subsequent in vivo studies employing murine tu-
mours, with no evidence of intrinsic toxicity.
The observation that LY294002 (4) exhibits lowmicromolar ATP-
competitive DNA-PK inhibitory activity (Ki = 6 lM)16 prompted ini-
tial efforts at Newcastle to develop a potent and selective DNA-PK
inhibitor. SAR studies included extensive modiﬁcation of the coreO N
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30heterocycle, with the 7,8-benzochromenone (22; NU7026) and
pyrimidoisoquinolinone (23) derivatives emerging as the most po-
tent of the series (DNA-PK; IC50 = 0.23 and 0.28 lM, respectively).34
Potency comparablewith 22 and 23was also found to reside in sim-
ple pyranone and thiopyranone derivatives, as exempliﬁed by 24
and 25 (DNA-PK; IC50 = 0.22 and 0.28 lM, respectively).35 By con-
trast, the analogous pyridones were weakly active or inactive (e.g.,
26, DNA-PK; IC50 > 100 lM), tentatively ascribed to the predomi-
nance of the putatively inactive 4-hydroxypyridine tautomer overthe active 4-pyridone. Although thesemonocycles offeredno advan-
tages over 22, evidence of weak ATM-inhibitory activity within the
pyran-4-one series directed studies that ultimately resulted in the
discovery of the potent ATM inhibitor KU-0055933 as discussed
below.Cellular studies conducted with 22 demonstrated that the
chromenone potentiated the in vitro growth-inhibitory activity
of topoisomerase II poisons in K562 leukaemia cells, and elicited
a concentration-dependent increase in DNA DSB formation and
G2/M checkpoint arrest in combination with etoposide.36
Although 22 also exhibited promising activity as a radiopotentiat-
ing agent in the CH1 human ovarian cancer cell line in vitro, pro-
longed exposure to the DNA-PK inhibitor proved necessary, and
pharmacokinetic evaluation demonstrated that 22 suffered rapid
plasma clearance as a consequence of extensive metabolism.37
The crucial role of the morpholine substituent was also estab-
lished from these early investigations, analogously to that ob-
served for the activity of 4 as a PI 3-K inhibitor, with the
corresponding piperidino analogue (27) proving some 10-fold less
potent as a DNA-PK inhibitor.34 Interestingly, whereas the 2,2-
dimethylmorpholine (28) and 2,6-dimethylmorpholine (29) deriv-
atives were very poorly active, the racemic 2-methylmorpholine
derivative (30) exhibited favourable activity against DNA-PK
(IC50 = 0.19 lM), and was observed to sensitise HeLa cells mark-
edly to ionising radiation in vitro.34O N
O
OS
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O
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lated compounds, the introduction of a range of groups at the
chromenone 6-, 7- and 8-positions, previously indicated to be tol-
erant to substitution, was investigated through a focussed com-
pound library approach.38 These efforts were rewarded by the
identiﬁcation of the dibenzothiophene (DBT) derivative NU7441
(31; IC50 = 30 nM) as a remarkably potent DNA-PK inhibitor, exhib-
iting good selectivity over other PIKK family members and a panel
of diverse kinases. More detailed biological studies established that
31 effectively potentiated the effects of ionising radiation and eto-
poside in human tumour cell lines in vitro and in vivo, albeit thatO N
O
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Ph
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S
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Spoor aqueous solubility proved to be a limiting factor for in vivo
studies.39,40 While less active than 31, the 8-(biphenyl-3-yl)chro-
men-4-one 32 also emerged from the compound library screen
as a respectable DNA-PK inhibitor (IC50 = 180 nM), with the non-
planar biphenyl motif offering an opportunity to probe alternative
regions of the ATP-binding domain. Subsequent SAR studies, where
a range of biaryl and heterobiaryl systems was investigated, re-
sulted in the identiﬁcation of the isosteric thiophen-2-yl (33) and
thiophen-3-yl (34) derivatives as potent DNA-PK inhibitors with
IC50 values of 18 and 20 nM, respectively.41 Unfortunately, com-
pounds 32–34 offered no advantages over 31 with regard to aque-
ous solubility.O N
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3In light of the poor aqueous solubility of 31, the KuDOS/New-
castle groups directed their efforts to improving the pharmaceuti-
cal properties of this promising lead DNA-PK inhibitor. Although
crystal structures of the DNA-PKcs have more recently become
available,42 these are not conducive to a structure-based com-
pound design approach owing to the poor resolutions obtained
for this very large protein. Nevertheless, the KuDOS/Newcastle
chemistry groups were able to construct a homology model of
the ATP-binding domain of DNA-PK indicative of regions of 31
amenable to the introduction of functionality, with the DBT 1-po-
sition appearing to be exposed to solvent. A variety of designs were
formulated whereby different linker motifs (e.g., ethers, benzylam-
ines and piperazines) were investigated at this position, through
the preparation of focussed compound libraries. Screening for both
DNA-PK inhibitory activity and in vitro radiopotentiation in HeLacells revealed a promising series of amide-linked DBT derivatives,
from which KU-0060648 (35; DNA-PK; IC50 = 5 nM)) was selected
for more detailed evaluation. The excellent in vitro potency of 35
translated into impressive activity in the in vivo setting; once daily
oral or IP dosing of 35 in mice greatly enhanced the efﬁcacy of IR in
the FADU head-and-neck human xenograft, with the compound
being generally well tolerated. Unfortunately, when dosed to rats
in toxicological studies, 35 induced a variety of untoward effects
that precluded its further development, and interpretation of the
in vivo data was also complicated by signiﬁcant PI 3-K-inhibitory
activity.With a view to improving the toxicity and selectivity proﬁle of
this inhibitor class, substitution elsewhere on the DBT ring of 31
was investigated. Encouragingly, transposition of the amide motif
of 35 to the DBT 8-position was found to confer improved, albeit
modest, selectivity for DNA-PK over PI 3-K family members as
exempliﬁed by 36. Although these derivatives were also efﬁcacious
when combined with IR in the FADU mouse xenograft model, the
toxicological and biopharmaceutical proﬁles of the candidates
did not justify further development work. Unfortunately, substitu-
tion elsewhere on the DBT ring was not beneﬁcial. Interestingly,
while the introduction of a methyl group at the DBT 3-position dra-
matically reduced potency against DNA-PK (37, IC50 = 2.5 lM), the
resultant restricted rotation about the chromenone-DBT bond en-abled the resolution of highly stable atropisomers. Moreover, a
clear stereochemical preference for DNA-PK inhibition was ob-
served, with activity residing exclusively in the laevorotatory
atropisomer of 37 (IC50 = 1.2 lM).43
Although ATM has attracted considerable interest as a therapeu-
tic target, very few useful inhibitors have been reported to date. The
radiosensitisation of tumour cells by caffeine (38) has been ascribed
to inhibition of ATM and ATR, but the pharmacological signiﬁcance
of this observation is questionable given the high concentrations of
the xanthine employed.44 Inspired by the PIKK-inhibitory activity of
wortmannin (1), Peng et al. identiﬁed a series of pyrroloquinoline
derivatives as irreversible ATM inhibitors (e.g., 39; IC50 = 0.6 lM),
with simple c-lactones (e.g., 40; IC50 = 0.25 lM) also exhibiting
activity comparable with 1.45 More recently, researchers at Pﬁzer
have identiﬁed CP466722 (41) as a highly selective and rapidly
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members or PI 3-K in a cellular setting.46 Importantly, effective sen-
sitisation to IR required only a transient exposure of tumour cells to
41, suggesting that therapeutic radiosensitisation may not necessi-
tate prolonged inhibition of ATM activity.N
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44The KuDOS-Newcastle group have also been active in the ATM
inhibitor ﬁeld. As mentioned above, evidence of weak ATM-inhibi-
tory activity within the pyran-4-one series (e.g., 24) prompted fur-
ther chemical library generation based on this scaffold. Diversity
synthesis, directed at replacing the 4-methoxyphenyl group in 24,
resulted in the identiﬁcation of KU-0055933 (42) as a potent and
selective ATM inhibitor (IC50 = 14 nM), with marked sensitisation
of cancer cells to IR and topoisomerase II inhibitors being demon-
strated.35,47 Further modiﬁcation of the thianthrene substituent of
42 was investigated, but minor structural changes were generally
detrimental to activity. Interestingly, a broad trend between the
shape of the pendant tricyclic substituent and activitywas adduced,
with non-planarity correlating with potent ATM inhibition.47
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The utility of 42 as an in vitro tool compound did not extend to
more detailed biological studies, owing to the poor aqueous solu-
bility of this highly lipophilic compound. In the absence of viable
structural biology data for ATM, and analogously to the DNA-PK
inhibitor studies described above, homology modelling was em-
ployed to guide the introduction of hydrophilic groups onto the tri-
cyclic substituent of 42 and related pyranones. Unfortunately,
while potency against ATM was retained for these derivatives
(e.g., 43 and 44), this was accompanied by poor cellular activity
compared with the parent inhibitor 42. However, subsequentstructural modiﬁcations were more fruitful, with the thioxanthene
45 combining potent ATM-inhibitory activity with excellent cellu-
lar activity, and the improved pharmaceutical properties of 45 has
facilitated detailed biological proﬁling of this ATM inhibitor.48As was the case for ATM, the literature is relatively bereft of dis-
closures of ATR inhibitors. Other than wortmannin (1) and caffeine
(38), the nitrosopyrimidine CDK2 inhibitor NU6027 (46) has been
described as a modest non-selective inhibitor of cellular ATR
(IC50 = 6.7 lM).49 The sensitisation of tumour cells to UV radiation
by the natural product schisandrin B (47) is also reportedly medi-
ated by ATR inhibition (IC50 = 7.3 lM).50
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A ﬂurry of recent patents and publications from researchers at
Vertex reﬂects the increasing interest in ATR inhibitors. A high-
throughput screening campaign identiﬁed the pyrazine derivative
48 as a promising ATP-competitive hit (ATR; IC50 = 0.62 lM), with
excellent selectivity over DNA-PK and ATM.11 The sub-optimal po-
tency and cellular activity of 48 was addressed by further elabora-
tion, guided by homology modelling of the ATP-binding domain of
ATR. Interestingly, the Vertex series does not utilise a morpholine
substituent, with the pyrazine N1 serving as the hydrogen bond
acceptor group for the interaction with the backbone NH of
Val2378, and the adjacent 2-amino groupdonating a hydrogenbond
to the carbonyl ofGlu2380.Anadditional interaction is postulated to
arise between the hydroxyl of the gatekeeper Tyr2365 and the
amide carbonyl group of 48, while the 6-phenyl ring of the inhibitor
makes a p-stacking interaction with Trp2370 of the kinase.51
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5358 M. Raymond V. Finlay, R. J. Grifﬁn / Bioorg. Med. Chem. Lett. 22 (2012) 5352–5359The increased potency and selectivity observed upon the intro-
duction of a 4-sulfonyl group (49; IC50 = 26 nM) was attributed to a
favourable interaction between the sulfone oxygen and the NH of
the ATR-speciﬁc residue Gly2385, with further optimisation result-
ing in the selection of 50 for more detailed biological evaluation.
Thus, 50 combines potent ATR-inhibitory activity (Ki = 6 nM) and
excellent cellular activity, with good physicochemical properties,
including aqueous solubility, and marked potentiation of the
in vitro cytotoxicity of IR and cisplatin was demonstrated. Of par-
ticular importance is the observation of a synthetic lethal effect of
50 in ATM-defective HCT116 colorectal cancer cells. Thus, the
inhibitor was shown to exhibit potent single-agent cytotoxicity
in vitro, whilst having negligible activity against a normal HFL1 cell
line. In addition, ATM-defective cells were preferentially sensitised
to IR by ATR inhibition with 50, whereas normal cells with func-
tional ATM were not sensitised. This implies that differentiation
between tumour and normal cells may potentially be achievable
when dosing these inhibitors to patients harbouring ATM deﬁcient
tumours. More recently, researchers at AstraZeneca/KuDOS have
demonstrated similar differentiation between ATM deﬁcient tu-
mour cells and healthy tissue with inhibitor 51, not only in an
in vitro setting, but also when dosed in vivo in mouse xenograft
models.52
Although the intense activity surrounding DNA-PK, ATM and
ATR inhibitors has yet to yield a marketed oncology medicine, con-
siderable progress has been made towards this goal. The availabil-
ity of selective small-molecule tool compounds with in vivo
activity, offers the opportunity to gain a deeper understanding of
the complex biology associated with these components of the
DDR, and a number of preclinical drug candidates have been iden-
tiﬁed. Further progress in building our understanding of the chem-
istry and biology of PIKK inhibitors will surely deliver useful
oncology therapies in the near future.
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